RS20050522A - Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation - Google Patents

Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation

Info

Publication number
RS20050522A
RS20050522A YUP-2005/0522A YUP20050522A RS20050522A RS 20050522 A RS20050522 A RS 20050522A YU P20050522 A YUP20050522 A YU P20050522A RS 20050522 A RS20050522 A RS 20050522A
Authority
RS
Serbia
Prior art keywords
protein kinase
therapeutic radiation
effects
increase
tricyclic compounds
Prior art date
Application number
YUP-2005/0522A
Other languages
English (en)
Inventor
Sacha Ninković
Michael Joh Bennett
Eugene Yuanjin Rui
Fen Wang
Suzanne Pritchett Benedict
Min Teng
Yong Wang
Jinjiang Zhu
Original Assignee
Pfizer Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc., filed Critical Pfizer Inc.,
Publication of RS20050522A publication Critical patent/RS20050522A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Abstract

Triciklična jedinjenja koja inhibiraju protein kinazu kao što je CHK-1, sa sledećom formulom (gde su R2, R3 i R4 kao što je odredjeno u specifikaciji) Farmaceutske kompozicije koje sadrže efikasne količine pomenutih jedinjenja ili njihovih soli, korisne su kao pojedinačni agens ili u kombinaciji sa antineoplastičnim agensom ili terapeutskim zračenjem koje ima anti-neoplastični efekat, za lečenje bolesti ili stanja kao što su kanceri.
YUP-2005/0522A 2003-01-09 2004-01-05 Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation RS20050522A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43939603P 2003-01-09 2003-01-09
PCT/IB2004/000026 WO2004063198A1 (en) 2003-01-09 2004-01-05 Diazepinoindole derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
RS20050522A true RS20050522A (en) 2007-12-31

Family

ID=32713475

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0522A RS20050522A (en) 2003-01-09 2004-01-05 Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation

Country Status (35)

Country Link
US (3) US6967198B2 (sr)
EP (2) EP1585749B1 (sr)
JP (1) JP3990718B2 (sr)
KR (1) KR100697746B1 (sr)
CN (1) CN1759118B (sr)
AP (1) AP2048A (sr)
AT (1) ATE404564T1 (sr)
AU (1) AU2004203977B2 (sr)
BR (1) BRPI0406701A (sr)
CA (1) CA2512683C (sr)
CR (1) CR7899A (sr)
CY (1) CY1108408T1 (sr)
DE (1) DE602004015724D1 (sr)
DK (1) DK1585749T3 (sr)
EA (1) EA009337B1 (sr)
EC (1) ECSP055911A (sr)
ES (1) ES2309484T3 (sr)
GE (1) GEP20084367B (sr)
HK (1) HK1086257A1 (sr)
HR (1) HRP20050624A2 (sr)
IL (1) IL169082A (sr)
IS (1) IS7884A (sr)
MA (1) MA27703A1 (sr)
MX (1) MXPA05007352A (sr)
NO (1) NO20053775L (sr)
NZ (1) NZ540638A (sr)
OA (1) OA13017A (sr)
PL (1) PL378372A1 (sr)
PT (1) PT1585749E (sr)
RS (1) RS20050522A (sr)
SI (1) SI1585749T1 (sr)
TN (1) TNSN05176A1 (sr)
UA (1) UA80733C2 (sr)
WO (1) WO2004063198A1 (sr)
ZA (1) ZA200504674B (sr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003214879B2 (en) * 2002-01-22 2008-02-07 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
ATE404564T1 (de) * 2003-01-09 2008-08-15 Pfizer Diazepinoindolderivate als kinaseinhibitoren
BRPI0607798A2 (pt) * 2005-02-18 2010-06-22 Astrazeneca Ab método para prognosticar uma responsividade do paciente a um inibidor de chk1, uso de um inibidor de chk1, e, kit para prognosticar uma resposta do paciente a um inibidor de chk1
SI1869020T1 (sl) 2005-03-29 2011-02-28 Icos Corp Derivati heteroaril uree, ki so uporabni za inhibicijo chk1
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP5180824B2 (ja) 2005-06-29 2013-04-10 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド ホスホルアミデートアルキル化剤プロドラッグ
US8324169B2 (en) * 2005-08-15 2012-12-04 The Regents Of The University Of California VEGF-activated ligands
JP4935675B2 (ja) 2005-08-25 2012-05-23 宇部興産株式会社 光学活性（Ｓ又はＲ）−α−アミノ酸及び光学活性（Ｒ又はＳ）−α−アミノ酸エステルの製造方法
AU2006282767A1 (en) * 2005-08-26 2007-03-01 The Regents Of The University Of California Non-steroidal antiandrogens
CA2648369A1 (en) * 2006-04-04 2007-10-11 Pfizer Products Inc. Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4?l)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
CN101415417A (zh) * 2006-04-04 2009-04-22 辉瑞产品公司 (2r,z)-2-氨基-2-环己基-n-(5-(1-甲基-1h-吡唑-4-基)-1-氧代-2,6-二氢-1h-[1,2]二氮杂卓并[4,5,6-cd]吲哚-8-基)乙酰胺的组合疗法
JP2010510222A (ja) * 2006-11-17 2010-04-02 シェーリング コーポレイション 増殖性障害に対する併用療法
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
JP5576370B2 (ja) * 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
EP2346881A1 (en) * 2008-10-10 2011-07-27 Priaxon AG Novel compounds which modulate kinase activity
US8314108B2 (en) 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
BR112013028665A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
EP2793882A4 (en) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA ACTIVATED DRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
MX2014008071A (es) 2011-12-31 2015-07-06 Beigene Ltd Tetra o penta-piridoftalazinonas ciclicas fusionadas como inhibidores de poli(adenosin-difosfato-ribosa)polimerasas.
NO2797921T3 (sr) * 2011-12-31 2018-02-03
CN102746211B (zh) * 2012-06-27 2015-05-27 上海泰坦化学有限公司 一种取代吲哚-3-甲醛类化合物的制备方法
TWI633107B (zh) * 2013-05-22 2018-08-21 開曼群島商百濟神州生物科技有限公司 作為ｐａｒｐ抑制劑的稠合四或五環二氫二氮呯并咔唑酮
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
PT3157566T (pt) 2014-06-17 2019-07-11 Vertex Pharma Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr
MX2018002322A (es) 2015-08-25 2018-04-11 Beigene Ltd Procedimiento para la preparacion de un inhibidor de poli(adp-ribosa)polimerasa, formas cristalinas, y usos del mismo.
CA3000684A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
WO2018059437A1 (en) 2016-09-27 2018-04-05 Beigene, Ltd. Treatment cancers using combination comprising parp inhibitors
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
WO2018157794A1 (en) 2017-02-28 2018-09-07 Beigene, Ltd. Crystalline forms of salts of fused tera or penta-cyclic dihydrodiazepinocarazolones, and uses thereof
US11661581B2 (en) * 2017-05-25 2023-05-30 University Of Massachusetts Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
NZ762985A (en) * 2017-09-22 2024-03-22 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN113631179A (zh) * 2019-01-25 2021-11-09 努梅迪公司 用于治疗特发性肺纤维化的方法
WO2021018298A1 (zh) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 作为parp抑制剂吲哚并七元酰肟化合物
CN114746413B (zh) 2019-11-29 2024-02-23 南京明德新药研发有限公司 二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用
CA3184988A1 (en) * 2020-07-13 2022-01-20 Ahmed Mamai Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof
US20230331739A1 (en) * 2020-07-31 2023-10-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analog crystal as parp inhibitor and method for preparing same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
EP1135135A4 (en) 1998-09-18 2006-08-09 Smithkline Beecham Corp CHK1 KINASE INHIBITORS
SI20691B (sl) * 1999-01-11 2008-10-31 Agouron Pharma Triciklični inhibitorji poli(ADP-riboza) polimeraz
ES2302699T3 (es) 1999-08-27 2008-08-01 Novartis Vaccines And Diagnostics, Inc. Oligonucleotidos quimericos antisentido y formulaciones de transfeccion celular de los mismos.
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6670167B1 (en) 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
DK1218494T3 (da) 1999-09-22 2005-08-08 Canbas Co Ltd Præparater og fremgangsmåder til inhibering af C2-cellecyklusstandsning og sensibilisering af celler til DNA-beskadigende midler
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
WO2002044183A2 (en) 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
ATE404564T1 (de) * 2003-01-09 2008-08-15 Pfizer Diazepinoindolderivate als kinaseinhibitoren

Also Published As

Publication number Publication date
US20050075499A1 (en) 2005-04-07
JP2006516274A (ja) 2006-06-29
NO20053775D0 (no) 2005-08-08
US7132533B2 (en) 2006-11-07
DE602004015724D1 (de) 2008-09-25
IS7884A (is) 2005-06-09
ZA200504674B (en) 2006-07-26
EA200500893A1 (ru) 2006-02-24
AP2005003353A0 (en) 2005-09-30
US20070135415A1 (en) 2007-06-14
AU2004203977A1 (en) 2004-07-29
EP1585749B1 (en) 2008-08-13
HRP20050624A2 (en) 2006-02-28
MA27703A1 (fr) 2006-01-02
IL169082A (en) 2011-02-28
CN1759118A (zh) 2006-04-12
ECSP055911A (es) 2005-11-22
DK1585749T3 (da) 2008-09-22
NO20053775L (no) 2005-09-16
WO2004063198A1 (en) 2004-07-29
EA009337B1 (ru) 2007-12-28
NZ540638A (en) 2007-12-21
CR7899A (es) 2005-08-05
UA80733C2 (en) 2007-10-25
EP1585749A1 (en) 2005-10-19
MXPA05007352A (es) 2006-02-17
KR20050092397A (ko) 2005-09-21
CA2512683C (en) 2010-03-16
CA2512683A1 (en) 2004-07-29
KR100697746B1 (ko) 2007-03-22
CN1759118B (zh) 2010-12-08
BRPI0406701A (pt) 2005-12-20
TNSN05176A1 (fr) 2007-06-11
PL378372A1 (pl) 2006-04-03
OA13017A (en) 2006-11-10
ATE404564T1 (de) 2008-08-15
US7462713B2 (en) 2008-12-09
AU2004203977B2 (en) 2010-06-17
ES2309484T3 (es) 2008-12-16
AP2048A (en) 2009-09-24
GEP20084367B (en) 2008-05-13
US6967198B2 (en) 2005-11-22
CY1108408T1 (el) 2014-02-12
PT1585749E (pt) 2008-10-23
HK1086257A1 (en) 2006-09-15
EP1947102A1 (en) 2008-07-23
SI1585749T1 (sl) 2008-10-31
JP3990718B2 (ja) 2007-10-17
US20060004052A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
RS20050522A (en) Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
BRPI0507644A (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
CY1112084T1 (el) Παραγωγα 5-φαινυλθειαζολης και χρηση ως αναστολεις της κινασης ρi3
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
MX2009005011A (es) Imidazopirazinas como inhibidores de proteina quinasa.
BR0315912A (pt) Compostos pirimìdicos com atividade antiproliferativa (ii)
HUP0303271A2 (hu) Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására
PT1678166E (pt) Inibidores de proteína-quinase
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
MX2007013624A (es) Inhibidores de proteina cinasa.
YU21404A (sh) Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka
IL197513A0 (en) Pyrazolopyrimidine derivatives and pharmaceutical compositions containing the same
TW200719899A (en) Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
TW200510384A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
ATE507218T1 (de) Benzodiazepin-derivate als rock-kinasen hemmer
BR0116123A (pt) Carbazóis antitumorais
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
TW200738680A (en) Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents
TW200602329A (en) Novel diazine derivatives, their manufacture and use as pharmaceutical agents
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
PL1684763T3 (pl) 6-arylo-7-halogeno-imidazo[1,2-a]pirymidyny jako środki przeciwnowotworowe
TW200626589A (en) Azole derivatives, their manufacture and use as pharmaceutical agents
PT1551850E (pt) 2 oxo-voruscharina e seus derivados
CU23421A3 (es) Derivados de diazepinoindol como inhibidores de quinasa